AUTX-703 has demonstrated potent growth inhibition in preclinical models of solid tumors and a hematological malignancy An overview of the Company’s AURIGIN platform to be presented at the American ...
NEWTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Auron Therapeutics has raised a $27 million Series B ...
An overview of the Company’s AURIGIN platform to be presented at the American Association for Cancer Research (AACR) 2024 Annual Meeting NEWTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Auron ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback